261.80
-0.87(-0.33%)
Currency In USD
| Previous Close | 262.67 |
| Open | 261.51 |
| Day High | 264.02 |
| Day Low | 252.61 |
| 52-Week High | 295.98 |
| 52-Week Low | 122.8 |
| Volume | 337,596 |
| Average Volume | 286,630 |
| Market Cap | 7.59B |
| PE | 42.23 |
| EPS | 6.2 |
| Moving Average 50 Days | 259.86 |
| Moving Average 200 Days | 184.81 |
| Change | -0.87 |
If you invested $1000 in Krystal Biotech, Inc. (KRYS) since IPO date, it would be worth $24,605.26 as of February 21, 2026 at a share price of $261.8. Whereas If you bought $1000 worth of Krystal Biotech, Inc. (KRYS) shares 5 years ago, it would be worth $3,403.09 as of February 21, 2026 at a share price of $261.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
GlobeNewswire Inc.
Feb 10, 2026 1:00 PM GMT
PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S.
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
GlobeNewswire Inc.
Feb 09, 2026 1:00 PM GMT
PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707,
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 11, 2026 6:00 PM GMT
Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, In